
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : CAM-101
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Recipient : Cambium Bio
Deal Size : $3.0 million
Deal Type : Financing
Cambium Bio Successfully Closes A$3.0M Financing Round
Details : The proceeds will primarily support the advancement of CAM-101 Elate Ocular through its registration-enabling Phase 3 clinical trials for dry eye disease.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
December 03, 2024
Lead Product(s) : CAM-101
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Recipient : Cambium Bio
Deal Size : $3.0 million
Deal Type : Financing
